Diurnal Group announces commercial launch of Efmody in the UK
LONDON, UK: Diurnal Group announced the commercial launch of Efmody (hydrocortisone modified-release hard capsules) in the United Kingdom as treatment of adult and adolescent patients...
Diurnal launches Efmody in Germany and Austria
LONDON: Diurnal Group plc announced the launch of Efmody (hydrocortisone modified-release hard capsules) in Germany and Austria as treatment of adult and adolescent patients (12...
Diurnal receives agreement from US FDA
LONDON, UK: Diurnal Group plc announced the US Food and Drug Administration (FDA) has agreed a Special Protocol Assessment (SPA) for Chronocort (modified-release hydrocortisone) for...